Frequently Asked Questions:
The COVID-19 pandemic created major hurdles to enterprises in the global bacteriophage therapy sector. With the inconsistencies in the transportation facility, obtaining raw materials for the production of medicine formulations was a major challenge. The COVID-19 epidemic hampered clinical trials in the United States, hurting key companies throughout the industry.
North America dominates the bacteriophages therapy market and will maintain its dominance throughout the projection period. This is because bacteriophage provides quick recovery and therapeutic impact, and rising healthcare expenditure would further boost the market’s development rate in this region.
The rise in the incidence of various antibiotic-resistant illnesses around the world is expected to help the worldwide bacteriophage market grow.
In terms of product, the phage probiotics sector held around 95.5 percent of the market in 2021.
Gastroenterology is creating a big opportunity for Bacteriophage Probiotic Manufacturers. Gut health is becoming a major public health concern, and phage supplements fill an unmet demand by protecting the gut from harmful bacteria.